REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Market Cap	$643.93M	P/E Ratio	N/A
52W High	$14.24	52W Low	$5.04
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-52.2%	52W Position	96.0%
Overall Score	60	Value Score	60
Quality Score	47	Technical Score	75

EPS Current Est	$-3.41	EPS Next Est	$-1.53
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGNX	$13.87	+7.94%	604.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RGNX	$13.87	+7.9%	604.48K
3
4
5
6

RGNX

RGNX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get REGENXBIO Inc. Data in Excel

Get REGENXBIO Inc. Data in Excel